Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After Allogeneic Hematopoietic Stem Cell Transplantation
NCT06449586Phase 3Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of letermovir in cytomegalovirus infection (CMV), sponsored by Ruijin Hospital. Started Jul 2024; status: active, not recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06449586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449586.